Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure.

King A, Doepner A, Turton D, Ciobota DM, Da Pieve C, Wong Te Fong AC, Kramer-Marek G, Chung YL, Smith G.

Org Biomol Chem. 2018 Apr 25;16(16):2986-2996. doi: 10.1039/c8ob00432c.

2.

HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.

Martins CD, Da Pieve C, Burley TA, Smith R, Ciobota DM, Allott L, Harrington KJ, Oyen WJG, Smith G, Kramer-Marek G.

Clin Cancer Res. 2018 Apr 15;24(8):1853-1865. doi: 10.1158/1078-0432.CCR-17-2754. Epub 2018 Feb 6.

PMID:
29437790
3.

Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.

Burley TA, Mączyńska J, Shah A, Szopa W, Harrington KJ, Boult JKR, Mrozek-Wilczkiewicz A, Vinci M, Bamber JC, Kaspera W, Kramer-Marek G.

Int J Cancer. 2018 Jun 1;142(11):2363-2374. doi: 10.1002/ijc.31246. Epub 2018 Jan 19.

PMID:
29313975
4.

Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges.

Martins CD, Kramer-Marek G, Oyen WJG.

Expert Opin Drug Deliv. 2018 Feb;15(2):185-196. doi: 10.1080/17425247.2018.1378180. Epub 2017 Sep 12.

PMID:
28893110
5.

Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89.

Allott L, Da Pieve C, Meyers J, Spinks T, Ciobota DM, Kramer-Marek G, Smith G.

Chem Commun (Camb). 2017 Jul 27;53(61):8529-8532. doi: 10.1039/c7cc03572a.

PMID:
28703825
6.

Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives.

Szopa W, Burley TA, Kramer-Marek G, Kaspera W.

Biomed Res Int. 2017;2017:8013575. doi: 10.1155/2017/8013575. Epub 2017 Feb 20. Review.

7.

Pre-clinical quantitative imaging and mouse-specific dosimetry for 111In-labelled radiotracers.

Denis-Bacelar AM, Cronin SE, Da Pieve C, Paul RL, Eccles SA, Spinks TJ, Box C, Hall A, Sosabowski JK, Kramer-Marek G, Flux GD.

EJNMMI Res. 2016 Dec;6(1):85. Epub 2016 Nov 25.

8.

Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors.

Da Pieve C, Allott L, Martins CD, Vardon A, Ciobota DM, Kramer-Marek G, Smith G.

Bioconjug Chem. 2016 Aug 17;27(8):1839-49. doi: 10.1021/acs.bioconjchem.6b00259. Epub 2016 Jul 19.

9.

Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside.

Kramer-Marek G, Oyen WJ.

J Nucl Med. 2016 Jul;57(7):996-1001. doi: 10.2967/jnumed.115.169540. Epub 2016 May 12. Review. No abstract available.

10.

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roulstone V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoo V, Harrington KJ.

Gene Ther. 2016 Apr;23(4):357-68. doi: 10.1038/gt.2016.5. Epub 2016 Jan 27.

11.

Computer-aided pulmonary image analysis in small animal models.

Xu Z, Bagci U, Mansoor A, Kramer-Marek G, Luna B, Kubler A, Dey B, Foster B, Papadakis GZ, Camp JV, Jonsson CB, Bishai WR, Jain S, Udupa JK, Mollura DJ.

Med Phys. 2015 Jul;42(7):3896-910. doi: 10.1118/1.4921618.

12.

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL, Bridges E, Capala J, Ioannis R, Harris AL, Kong A.

Oncotarget. 2014 Aug 15;5(15):5934-49.

13.

Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies.

Adesina SK, Holly A, Kramer-Marek G, Capala J, Akala EO.

J Pharm Sci. 2014 Aug;103(8):2546-55. doi: 10.1002/jps.24061. Epub 2014 Jun 24.

14.

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A.

Oncotarget. 2014 Aug 30;5(16):6633-46.

15.

Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions.

Kramer-Marek G, Gore J, Korc M.

Cancer Lett. 2013 Dec 1;341(2):132-8. doi: 10.1016/j.canlet.2013.08.008. Epub 2013 Aug 11. Review.

16.

Automated computer quantification of breast cancer in small-animal models using PET-guided MR image co-segmentation.

Bagci U, Kramer-Marek G, Mollura DJ.

EJNMMI Res. 2013 Jul 5;3(1):49. doi: 10.1186/2191-219X-3-49.

17.

Immuno-PET of the hepatocyte growth factor receptor Met using the 1-armed antibody onartuzumab.

Jagoda EM, Lang L, Bhadrasetty V, Histed S, Williams M, Kramer-Marek G, Mena E, Rosenblum L, Marik J, Tinianow JN, Merchant M, Szajek L, Paik C, Cecchi F, Raffensperger K, Jose-Dizon JM, Bottaro DP, Choyke P.

J Nucl Med. 2012 Oct;53(10):1592-600. doi: 10.2967/jnumed.111.102293. Epub 2012 Aug 23.

18.

Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy.

Mitsunaga M, Nakajima T, Sano K, Kramer-Marek G, Choyke PL, Kobayashi H.

BMC Cancer. 2012 Aug 8;12:345. doi: 10.1186/1471-2407-12-345.

19.

Recent advances in optical cancer imaging of EGF receptors.

Kramer-Marek G, Longmire MR, Choyke PL, Kobayashi H.

Curr Med Chem. 2012;19(28):4759-66. Review.

PMID:
22873662
20.

PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG.

Kramer-Marek G, Bernardo M, Kiesewetter DO, Bagci U, Kuban M, Aras O, Zielinski R, Seidel J, Choyke P, Capala J.

J Nucl Med. 2012 Jun;53(6):939-46. doi: 10.2967/jnumed.111.100354. Epub 2012 May 11. Erratum in: J Nucl Med. 2012 Jul;53(7):1169. Omer, Aras [corrected to Aras, Omer].

Supplemental Content

Loading ...
Support Center